What are the clinical features, causes, and management of drug‑induced parkinsonism (DIP)?

Drug-Induced Parkinsonism (DIP)

Drug-induced parkinsonism is a reversible parkinsonian syndrome caused by dopamine receptor-blocking agents, most commonly antipsychotics, characterized by action tremors, rigidity, bradykinesia, and postural instability with minimal asymmetry, requiring prompt recognition and discontinuation or dose reduction of the offending agent for optimal recovery. 1

Clinical Features

DIP presents with the classic parkinsonian tetrad but with distinguishing characteristics:

• Tremor: Predominantly action tremor (not resting tremor as in idiopathic Parkinson's disease)
• Rigidity: Muscular stiffness with cogwheel rigidity
• Bradykinesia: Slowness of movement and shuffling gait
• Postural instability: Balance difficulties

Critical distinguishing feature: DIP typically shows minimal lateral asymmetry, whereas idiopathic Parkinson's disease characteristically presents with asymmetrical onset 2, 3, 4.

The onset is typically subacute, occurring within days to weeks after initiating or increasing the dose of dopamine receptor-blocking agents 1.

Causative Medications

The primary culprits are dopamine receptor-blocking agents (DRBAs):

• Typical (first-generation) antipsychotics: Haloperidol, thioridazine, chlorpromazine - carry higher risk
• Atypical (second-generation) antipsychotics: Risperidone, olanzapine (lower risk with quetiapine, aripiprazole, and clozapine)
• Other DRBAs: Metoclopramide, prochlorperazine, and other antiemetics

High-potency typical antipsychotics produce more extrapyramidal symptoms, while low-potency agents cause more anticholinergic effects 5.

Diagnosis

Diagnosis requires three elements:

1. Medication history: Document exposure to DRBAs
2. Clinical presentation: Parkinsonian features with minimal asymmetry
3. Exclusion of other causes: Rule out idiopathic Parkinson's disease and other parkinsonian syndromes

Ancillary Testing

When the diagnosis is uncertain or symptoms persist after drug withdrawal:

• DaTscan (ioflupane-123 SPECT): Normal in pure DIP; abnormal suggests underlying prodromal Parkinson's disease that was "unmasked" by the medication 3, 6
• Skin biopsy: Can detect alpha-synuclein deposits to differentiate from idiopathic Parkinson's disease 4

Critical pitfall: Some patients have underlying prodromal Parkinson's disease that becomes clinically apparent ("unmasked") when exposed to DRBAs. These patients will have abnormal DaTscans and may require levodopa treatment 3, 6.

Management

The cornerstone of treatment is early diagnosis and rapid withdrawal of the offending agent, which improves the possibility of complete recovery 1.

Treatment Algorithm:

Step 1: Discontinue or reduce the causative agent

• If the DRBA can be stopped safely, discontinue immediately
• Weigh the severity of the underlying psychiatric or medical condition requiring the medication 7

Step 2: For patients requiring continued antipsychotic therapy (e.g., schizophrenia)

• Switch to lower-risk agents: Quetiapine or clozapine preferred 2, 4
• Aripiprazole is another option with minimal DIP risk 1
• Reduce dose of current antipsychotic if switching is not feasible

Step 3: Symptomatic treatment if needed

• Anticholinergic agents: Benztropine or trihexyphenidyl for symptomatic relief 1, 8
• Dopaminergic agonists: Amantadine as alternative 1
• Levodopa: Reserved for patients with confirmed underlying prodromal Parkinson's disease on DaTscan 3

Important caveat: Prophylactic anticholinergics are NOT indicated and should only be used for established symptoms 4. However, in patients at high risk for acute dystonia (young males on high-potency agents) or with history of dystonic reactions, prophylaxis may be considered to prevent this specific complication 5.

Step 4: Monitor recovery

• Symptoms typically improve within weeks to months after drug withdrawal
• Persistent symptoms beyond 6 months suggest underlying neurodegenerative disease requiring DaTscan evaluation

Prevention Strategy

In patients requiring antipsychotics:

• Start with second-generation agents (quetiapine, clozapine, aripiprazole)
• Use lowest effective dose
• Regular neurological monitoring for early detection 2, 6
• Avoid combining multiple DRBAs

Critical distinction from other extrapyramidal syndromes: DIP differs from acute dystonia (occurs after first few doses, involves muscle spasms), akathisia (subjective restlessness within days), and tardive dyskinesia (involuntary facial movements after chronic use) 1, 5, 1.